Human TRIM14 knockout A549 cell line
Be the first to review this product! Submit a review
|
(0 Publication)
TRIM14 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 10 bp deletion in exon 4 and 2 bp deletion in exon 4 and 40 bp deletion in exon 4.
View Alternative Names
5830400N10Rik, KIAA0129, TRI14_HUMAN, TRIM14, Tripartite motif-containing protein 14, pub, tripartite motif protein 14, tripartite motif protein TRIM14, tripartite motif-containing 14
- Sanger seq
Unknown
Sanger Sequencing - Human TRIM14 knockout A549 cell line (AB267175)
Allele-2 : 10 bp deletion in exon 4.
- Sanger seq
Unknown
Sanger Sequencing - Human TRIM14 knockout A549 cell line (AB267175)
Allele-3 : 2 bp deletion in exon 4.
- Sanger seq
Unknown
Sanger Sequencing - Human TRIM14 knockout A549 cell line (AB267175)
Allele-1 : 40 bp deletion in exon4
Product details
Recommended control: Human wild-type A549 cell line (ab255450). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
What's included?
Properties and storage information
Gene name
Gene editing type
Gene editing method
Knockout validation
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Handling procedures
Initial handling guidelines
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.
Subculture guidelines
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 2x104 cells/cm2 is recommended.
- Cells should be passaged when they have achieved 80-90% confluence.
- Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium
F-12K + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
TRIM14 plays a role in innate immune response by modulating signaling pathways. It does not have E3 ubiquitin ligase activity like other TRIM family members but interacts with proteins in antiviral defenses. TRIM14 associates with the mitochondria contributing to the formation of complexes with proteins like MAVS which are involved in the antiviral response to RNA viruses.
Pathways
TRIM14 is integral to the regulation of innate immune signaling pathways. It participates in the RIG-I-like receptor signaling pathway essential for detecting viral RNA. TRIM14 does this through interaction with MAVS leading to the activation of downstream signaling proteins including NF-kB and IRF3. These proteins result in the production of type I interferons and pro-inflammatory cytokines.
Quality control
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 1 US: 1
Adherent/suspension
Adherent
Gender
Male
Complementary Products
Primary Antibodies
AB125001
Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106]
RabMAb|Recombinant|KO Validated
![Immunocytochemistry/ Immunofluorescence - Anti-Retinoid X Receptor alpha/RXRA antibody [EPR7106] (AB125001)](https://content.abcam.com/products/images/retinoid-x-receptor-alpha-rxra-antibody-epr7106-ab125001--immunocytochemistry-immunofluorescence-img408362.jpg)
- 5
- 5
![Immunocytochemistry/ Immunofluorescence - Anti-PPAR gamma antibody [EPR23297-111] (AB272718)](https://content.abcam.com/products/images/ppar-gamma-antibody-epr23297-111-ab272718--immunocytochemistry-immunofluorescence-img428948.jpg)
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com